/
Nephros is a commercial-stage company that develops and markets high-performance water filtration solutions for points of use, with a core focus on medical-grade water filtration. Our medical filtration portfolio includes two product lines: infection control and dialysis water.
$3.78
+$0.02 (+0.53%)
EOD Jul 17, 2026
Operating margin is thin at 6.10%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 32.7% YoY with margins expanding 6.1pp.
At 54x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
54.0x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$19M
▲ +32.7% YoY
Net Income (TTM)
$776K
▲ +1513.5% YoY
Op. Margin
3.54%
▲ +6.1pp YoY
ROIC
5.92%
▲ +10.6pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$348K
▲ +434.3% YoY
Net Debt
-$3M
Net Cash Position
Cash & Equiv.
$4M
5Y CAGR: +17.0%
Continue Research
At a P/E of 54.0, Nephros (NEPH)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Nephros scores 44/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Nephros scores 44 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 3.5% operating margin and a 5.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh NEPH's valuation and scores 44/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.